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Abstract
Dengue often presents with non-specific clinical signs, and given the current paucity of accurate, rapid diagnostic
laboratory tests, identifying easily obtainable bedside markers of dengue remains a priority. Previous studies in febrile Asian
children have suggested that the combination of a positive tourniquet test (TT) and leucopenia can distinguish dengue
from other febrile illnesses, but little data exists on the usefulness of these tests in adults or in the Americas. We evaluated
the diagnostic accuracy of the TT and leucopenia (white blood cell count ,5000/mm
3) in identifying dengue as part of an
acute febrile illness (AFI) surveillance study conducted in the Emergency Department of Saint Luke’s Hospital in Ponce,
Puerto Rico. From September to December 2009, 284 patients presenting to the ED with fever for 2–7 days and no
identified source were enrolled. Participants were tested for influenza, dengue, leptospirosis and enteroviruses. Thirty-three
(12%) patients were confirmed as having dengue; 2 had dengue co-infection with influenza and leptospirosis, respectively.
An infectious etiology was determined for 141 others (136 influenza, 3 enterovirus, 2 urinary tract infections), and 110
patients had no infectious etiology identified. Fifty-two percent of laboratory-positive dengue cases had a positive TT versus
18% of patients without dengue (P,0.001), 87% of dengue cases compared to 28% of non-dengue cases had leucopenia
(P,0.001). The presence of either a positive TT or leucopenia correctly identified 94% of dengue patients. The specificity
and positive predictive values of these tests was significantly higher in the subset of patients without pandemic influenza A
H1N1, suggesting improved discriminatory performance of these tests in the absence of concurrent dengue and influenza
outbreaks. However, even during simultaneous AFI outbreaks, the absence of leucopenia combined with a negative
tourniquet test may be useful to rule out dengue.
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Introduction
Dengue, the disease caused by four related but distinct dengue
viruses (DENV), is now considered the most important arthropod-
borne disease worldwide. It is transmitted through the bite of an
infected mosquito, usually Aedes aegypti or Aedes albopictus [1], and is
endemic to tropical and subtropical regions. Dengue affects 50–
100 million people each year. In 2007, more than 890,000 dengue
cases were reported in the Americas. Globally, 500,000 patients
with dengue, mostly children, require hospitalization and at least
12,500 die each year [2]. There is significant year-to-year va-
riation in the incidence of dengue, with large outbreaks typically
occurring in 3- to 5-year cycles.
Island-wide epidemics of dengue have been identified in Puerto
Rico since 1915 [3] but similar to other countries in the Western
Hemisphere, dengue epidemics have increased in frequency and
severity over the past 20 years [4]. During the last large island-wide
dengue outbreak in 2007, disease appeared to be more severe than
in previous large outbreaks, with more hospitalizations and cases of
dengue hemorrhage fever (DHF), and a high proportion of cases
with hemorrhagic manifestations [5]. In 2007, a total of 10,508
suspected dengue cases were reported to the passive dengue
surveillance system (PDSS) in Puerto Rico; 53% were hospitalized,
32% had hemorrhage and less than 1% died. One lesson learned
from this outbreak was that most of the laboratory-confirmed fatal
cases had a delay in diagnosis and treatment initiation, highlighting
the importance of timely dengue diagnosis [5].
While morbidity and mortality has been linked to delayed
provision of supportive treatment [6], case fatality rates for severe
dengue infections, including DHF and dengue shock syndrome
(DSS), can be reduced from 10% to 20% to less than 1% with
early diagnosis and proper treatment [7–8]. However, there is no
rapid, point-of-care diagnostic test available, and the clinical
diagnosis of dengue may be challenging, as it usually presents with
non-specific symptoms, including fever, headache and myalgia.
Therefore, dengue is difficult to distinguish from other AFIs, such
www.plosntds.org 1 December 2011 | Volume 5 | Issue 12 | e1400as influenza, leptospirosis, and enteroviral infections. In 2007, a
simultaneous outbreak of acute gastroenteritis and dengue at the
height of the dengue outbreak made recognition of dengue
difficult, especially among those with warning signs for severe
dengue such as persistent vomiting and abdominal pain. The
concurrent outbreaks threatened to overwhelm the emergency and
inpatient capacity of many Puerto Rican hospitals. In addition,
simultaneous outbreaks of dengue and leptospirosis [9], dengue
and measles [10], and dengue and influenza [11] in Puerto Rico
caused similar difficulties with the clinical recognition, diagnosis,
and management of dengue in the past.
The tourniquet test (TT) has been recommended as a tool to
differentiate dengue from other AFIs [12]. Studies from Thailand
found that a positive TT in combination with leucopenia could
distinguish dengue from other AFI in children [13–15]. The aim of
our study was to evaluate the accuracy and usefulness of the TT
and leucopenia (white blood cell count ,5,000/mm
3)i n
identifying dengue among patients with AFI in a setting with a
large number of adult cases and during concurrent dengue and
influenza outbreaks.
Materials and Methods
Ethics statement
The study design and consent process was approved by the
Institutional Review Boards (IRB) at the Centers for Disease
Control and Prevention (CDC protocol # 5638) and Ponce
University School of Medicine. Written consent was not required
by the IRB as data was analyzed anonymously, the project was
considered enhanced public health surveillance and the risk to the
patient was considered minimal to none. Data was stripped of
personal identifiers for analysis purposes and the database did not
include any information that could link back to individual patients.
Dengue is reportable by law in Puerto Rico and this project used
the same reporting form used in the PDSS and no additional blood
specimens were obtained in this project beyond what are normally
collected for routine surveillance. Verbal consent was obtained for
performing nasopharyngeal testing for influenza and for conduct-
ing the tourniquet test, a standard non-invasive dengue diagnostic
test. A patient information sheet in Spanish written at an
elementary-school level explaining the purpose of the study and
the rationale and nature of these tests was read to and given to the
patient. Verbal consent for performance of the influenza testing
was documented by recording the results of the rapid influenza test
on a separate sheet. The bottom half of the sheet, with explanation
of test results in Spanish, was given to the patient and the top half
was kept in a locked cabinet inside a secure CDC facility with
access available only to study investigators.
Study population
The PDSS in Puerto Rico has been in operation for more than
30 years as previously described [5]. In 2009, the PDSS at the
Saint Luke’s Episcopal Hospital, in Ponce, Puerto Rico, was
augmented to include surveillance for all AFI. Children and adults
presenting to the emergency department (ED) were eligible for
enrollment if they met the following case definition of AFI:
documented fever of $38.0uC at presentation to the ED or history
of fever that persists for 2 to 7 days without identified source of
fever. Those with an identifiable source of fever, including but not
limited to diagnoses of otitis media, sinusitis, pneumonia, cellulitis,
impetigo, wound infection, pyelonephritis, osteomyelitis or vari-
cella were excluded. Saint Luke’s Episcopal Hospital is a 425 bed
tertiary care hospital that serves more than 54,000 patients in their
ED each year. The Saint Luke’s Episcopal Hospital is one of the
largest hospitals outside of the San Juan metropolitan area and
serves as the primary referral hospital for a population of more
than 500,000 people in southern Puerto Rico [16].
Study protocol
The surveillance period was from September 29, 2009 through
December 18, 2009. All patients presenting for medical care at the
ED of Saint Luke’s Episcopal Hospital who met the case definition
above were enrolled in the surveillance system. At the time of
enrollment, study personnel explained the purpose of the surveil-
lance project and obtained verbal consent for participation.
Participants were interviewed to collect demographic data included
on the standard PDSS data collection form, including age, sex, place
of residence, and days from symptom onset to specimen collection.
Clinical data that were recorded included the duration of fever, the
presenceorabsenceofheadache,eyepain, myalgia,arthralgia, rash,
nausea and vomiting, and hemorrhagic manifestations, including
positive TT. Laboratory data recorded on the form include white
blood cell count, platelet count, and highest and lowest hematocrit
values. Performance of a white blood cell count, blood and urine
cultures and other laboratory tests were at the discretion of the
attendingphysicianinthecourseofroutinepatientcarebutwerenot
part of the study protocol. For all patients, a blood sample and two
nasopharyngeal samples were collected for diagnostic testing.
A TT was performed by trained study personnel. The standard
TT was performed by inflating a blood pressure (BP) cuff on the
upper arm of the patient to a point mid way between their systolic
and diastolic pressure for 5 minutes, and then counting the
number of petechiae in a 2.5 cm
2 area on the volar aspect of the
forearm just distal to the antecubital fossa 2 minutes after releasing
the BP cuff. The TT was considered positive if 10 or more
petechiae were identified. Leucopenia was defined as a total white
blood cell count of ,5,000/mm
3, in keeping with previously
published criteria from Asia and the Americas [15,17].
Laboratory testing
Two nasopharyngeal samples were obtained. The first sample
was tested onsite by using the QuikVue Influenza A + Br a p i d
Author Summary
In the Americas, the incidence and severity of dengue
cases has increased dramatically in the past 30 years. Early
diagnosis and initiation of appropriate therapy can
substantially reduce dengue morbidity and mortality.
However the absence of a point-of-care diagnostic test
and the non-specific clinical signs and symptoms in early
disease make differentiating dengue from other acute
febrile illnesses challenging. Identifying dengue during an
outbreak of another disease is especially difficult. The
combination of a simple bedside test, the tourniquet test
(TT), and a readily available laboratory test, the white
blood cell count, has been reported to be a useful triage
tool for identifying children with dengue in Asia, but little
information exists on the performance of these tests in the
Americas or among adults. We evaluated the utility of
these tests in the setting of a concurrent influenza
epidemic in Puerto Rico in 2009. A positive TT or
leucopenia (white blood cell count ,5000) was present
in 94% of patients with laboratory proven dengue. Patients
without either of these findings rarely had dengue. Our
study indicates that a combination of two rapid, widely
available tests can assist clinicians in distinguishing
dengue from other illnesses with similar signs and
symptoms.
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second sample placed in viral transport media and refrigerated
until transport to the CDC’s Dengue Branch for confirmatory
influenza testing by polymerase chain reaction (PCR) testing. A
5–10 ml venous blood sample was collected, immediately
refrigerated at 4uC, centrifuged on site, and transported on ice
within 3 days to the Dengue Branch for further testing. Samples
were initially tested for the presence of DENV via serotype-
specific reverse-transcriptase PCR (RT-PCR) [18–19], DENV-
specific non-structural protein-1 assay (NS-1) [20], and an anti-
DENV IgM enzyme-linked immunosorbent assay (MAC-ELISA)
[21]. Samples with sufficient quantity of serum remaining were
subsequently transported on ice to the Bacterial Zoonosis Branch
of the CDC in Atlanta for testing for leptospirosis. Specimens
were screened for IgM antibodies to leptospirosis by using the
rapid dipstick ELISA ImmunoDOT kit (GenBio, Inc., San
Diego, CA). Specimens with positive or borderline results with
the ImmunoDOT kit were further tested by using the micro-
scopic agglutination test (MAT) [22]. Patient sera were serially
diluted in the MAT and mixed with a panel of 20 Leptospira
reference antigens that represented 17 serogroups. Resulting
agglutination titers were read by using darkfield microscopy, and
the final titer was expressed as the reciprocal of the last well that
agglutinates 50% of the antigen. Samples from patients with
illness of ,3 days duration and with sufficient sera remaining
were shipped at 270uC to the Picornavirus Laboratory at CDC
and tested for enteroviruses by a pan-enterovirus real-time RT-
PCR by using primers and probe targeting the 59 non-translated
region [23]. In PCR-positive specimens, the enterovirus type was
identified by semi-nested PCR amplification and sequencing of a
portion of the region encoding the VP1 capsid protein, as
previously described [24]. All personnel performing laboratory
testing were unaware of the clinical condition of the patient
including TT and WBC count results.
Analyses
Data was initially entered into a Microsoft Access database
(Access 2007; Redmond WA) and exported to SAS version 9.2
(SAS Institute, Cary, NC). We calculated the sensitivity, specificity,
positive predictive value (PPV), and negative predictive value
(NPV) of leucopenia and a positive TT, both in isolation and in
combination, to differentiate dengue from other AFI. Proportions
were compared using X2 test or Fisher’s exact test as appropriate.
For each test, statistical significance was considered to be a P
value#0.05.
Results
A total of 284 patients with AFI were enrolled. Thirty-one
(11%) patients were laboratory confirmed as having dengue, 136
(48%) influenza and 3 (1%) were diagnosed with enterovirus. Dual
infections were confirmed in two additional patients; one patient
had influenza and dengue and the other had influenza and
leptospirosis. These two patients were excluded from data analysis.
Urinary tract infections were found in two patients (Escherichia coli
and Staphlococcus saprophyticus). None of the patients had a positive
blood culture. No etiology was identified among the remaining
110 enrolled patients. Serotype information was available by PCR
from 20/31 laboratory-confirmed pure dengue infections, 18 were
DENV-4 and 1 each were DENV-1 and DENV-2.
A TT was performed on 247 (88%) patients, of whom 54 (22%)
had a positive result (Table 1).No patient had an adverse event from
performanceof the TTorwasunableto tolerate the procedure.Half
(52%) of the patients with laboratory-confirmed dengue had a
positive TT while 18% of patients with influenza and 17% of
patients with other AFI had a positive TT. WBC results were
available for 276 (98%) patients. Dengue patients were also
significantly more likely to have leucopenia (87%) than influenza
patients (44%, P,0.001) and patients with other AFI (12%,
P,0.001). Forty five percent of dengue patients had a positive TT
and leucopenia, whereas ,10% of patients with either influenza
(7%, P,0.0001) oranotherAFI (5%, P,0.0001) had both a positive
TT and leucopenia. Almost all (94%) dengue patients had either a
positive TT or leucopenia compared with 57% of influenza patients
and 26% of patients with other AFI.
When compared by age group, a positive TT was more
common among laboratory-confirmed dengue patients aged #15
years than dengue patients .15 years old (67% vs. 46%), but this
difference was not statistically significant (P=0.43) (Table 2).
Among patients aged #15 years, dengue patients were more likely
to have a positive TT (67%) than patients with influenza (18%) or
other AFI (17%). However, dengue patients were not more likely
to have leucopenia when compared with influenza patients in this
age group (67% vs. 54%, respectively, P=0.98). Among patients
.15 years old, a higher proportion of patients with dengue had
leucopenia (96%) when compared with influenza patients (33%)
and patients with other AFI (11%) (P,0.001). The proportion of
dengue patients who presented with both a positive TT and
leucopenia was similar for both age groups (44% vs. 46%). A
higher proportion of dengue patients were positive for both tests
either alone or in combination when compared with patients with
Table 1. Tourniquet test and leucopenia results among patients with dengue, influenza or other AFI.
Diagnosis TT Leucopenia* TT and Leucopenia TT or Leucopenia
Pos Neg % Pos 95% CI
{ PV** Pos Neg % Pos 95% CI PV Pos Neg % Pos 95% CI PV Pos Neg % Pos 95% CI PV
Dengue
(n=31)
16 15 52 0.35–
0.68
— 27 4 87 0.71–
0.95
— 14 17 45 0.29–
0.62
— 29 2 94 0.79–
0.98
–
Influenza
(n=136)
21 97 18 0.12–
0.26
0.001 56 76 44 0.34–
0.51
0.001 8 107 7 0.04–
0.13
0.0001 69 53 57 0.48–
0.65
0.0001
Other AFI
"
(n=115)
17 81 17 0.11–
0.27
0.002 13 100 12 0.07–
0.19
0.001 5 92 5 0.02–
0.12
0.0001 25 73 26 0.18–
0.35
0.0001
TT=tourniquet test; Pos=positive; Neg=negative; CI=confidence interval.
*Leucopenia defined as a white cell count of ,5,000.
**PV=P values for difference in proportion between dengue and influenza patients and dengue and other AFI patients using X
2 and Fisher’s exact test.
{Calculated via Wilson Score Interval method.
"Other AFI does not include patients with dengue or influenza.
doi:10.1371/journal.pntd.0001400.t001
Tourniquet Test and WBC Count in Dengue and AFI
www.plosntds.org 3 December 2011 | Volume 5 | Issue 12 | e1400influenza and patients with other AFI regardless of the patient’s
age. However, the difference was only statistically significant
among patients in the older age group.
The TT used alone correctly identified half (sensitivity 52%) of
the patients who had dengue (Table 3). The TT performed better
in identifying patients who did not have dengue (specificity 82%),
and a negative TT was highly associated with the absence of
disease (NPV 92%). Neither the specificity nor the NPV of the TT
changed significantly when influenza patients were excluded. In
contrast, the presence of leucopenia alone identified most
laboratory-confirmed dengue cases (sensitivity 87%). However,
the specificity of leucopenia was less than that of the TT (specificity
72% vs. 82%, respectively), and it was highly affected by the
presence of influenza patients. The combination of a negative TT
and normal white cell count correctly identified most patients who
did not have dengue (94% specificity), whereas having either a
positive TT or leucopenia correctly identified a similar proportion
of patients with dengue (94% sensitivity).
The relationship between TT results and platelet count, a
marker of disease severity in dengue, is shown in Table 4. A
positive TT was associated with laboratory-confirmed dengue in
patients with a platelet count greater than 100,000 (P=0.0001)
but not in patients with a platelet count below this level. For
patients without dengue, no association was seen between the
platelet level and a positive TT.
Discussion
Our study sought to evaluate the usefulness of a positive TT
and leucopenia alone and in combination in identifying patients
with dengue among children and adults with AFI in an ED of a
dengue endemic area. Previous studies examining the use of one
or both of these tests have primarily been performed in Asia
among children suspected to have dengue and who required
hospital admission [13–15,25–27]. While direct comparisons
with the results of Asian studies are difficult because of
differences in disease epidemiology and study design, our study
supports the findings of previous studies conducted in Thailand
[14,15], which found that the presence of either leucopenia, a
positive TT, or both is helpful in distinguishing between
patients with and without dengue. In our study and others
Table 2. Tourniquet test and leucopenia as diagnostics markers among patients by age group.
Tourniquet Test (TT)
Leucopenia
(,5000 wbc/mm
3) TT and leucopenia TT or leucopenia
Diagnosis Pos Neg % Pos 95% CI* Pos Neg % Pos 95% CI* Pos Neg % Pos 95% CI* Pos Neg % Pos 95% CI*
Age#15 years
Dengue 6 3 67 0.35–0.88 6 3 67 0.35–0.88 4 5 44 0.19–0.73 8 1 89 0.57–0.98
Influenza 9 41 18 0.10–0.31 29 25 54 0.41–0.66 4 45 8 0.03–0.19 34 19 64 0.51–0.76
Other AFI
{ 8 38 17 0.09–0.31 7 51 12 0.06–0.23 2 44 4 0.01–0.15 13 33 28 0.17–0.43
Age.15 years
Dengue 10 12 46 0.27–0.65 21 1 96 0.78–0.99 10 12 46 0.26–0.65 21 1 96 0.78–0.99
Influenza 12 56 18 0.10–0.28 27 51 33 0.24–0.44 4 62 6 0.02–0.15 35 34 51 0.39–0.62
Other AFI
{ 9 43 18 0.10–0.30 6 49 11 0.05–0.21 3 47 6 0.02–0.16 12 40 23 0.14–0.37
TT=tourniquet test; AFI=acute febrile illness; CI=confidence interval; Pos=positive; Neg=negative, wbc=white blood cells, mm
3=cubic milliliter.
*Calculated via Wilson Score Interval method.
{Other AFI does not include patients with dengue or influenza.
doi:10.1371/journal.pntd.0001400.t002
Table 3. Sensitivity, specificity, and predictive values of
tourniquet test and leucopenia for laboratory-confirmed dengue.
Tourniquet
Test (TT)
(95% CI)
Leucopenia
(95% CI)
TT &
Leucopenia
(95% CI)
TT or
Leucopenia
(95% CI)
All patients
(n=282)*
Sensitivity 51.6 (33–69) 87.1 (69–96) 45.2 (28–64) 93.6 (77–99)
Specificity 82.4 (76–87) 71.8 (66–77) 93.9 (89–96) 57.2 (50–64)
PPV 29.6 (18–43) 28.1 (19–38) 51.9 (31–69) 23.6 (17–32)
NPV 92.2 (87–95) 97.8 (94–99) 92.1 (88–95) 98.4 (94–99)
All patients
except
influenza
patients
(n=146){
Sensitivity 51.6 (33–69) 87.1 (69–96) 45.2 (28–64) 93.6 (77–99)
Specificity 82.7 (73–89) 88.5 (81–93) 94.9 (88–98) 73.7 (64–82)
PPV 48.5 (31–66) 67.5 (51–81) 73.7 (49–90) 53.7 (39–66)
NPV 84.4 (75–91) 96.2 (90–99) 84.4 (76–90) 97.2 (90–99)
TT=tourniquet test; PPV=Positive Predictive Value; NPV=Negative Predictive
Value.
*Data available on TT results for 247 patients and for WBC count for 276
patients.
{Data available on TT results for 129 patients and for WBC count for 144
patients.
doi:10.1371/journal.pntd.0001400.t003
Table 4. Percent of positive tourniquet tests for lab-confirmed
dengue versus non–dengue patients by platelet count.
Diagnosis Platelets#100K Platelets.100K
No. % PV* No. % PV*
Dengue 9/22 40.9 0.672 7/9 77.8 0.0001
Non-dengue 2/8 25.0 35/205 17.5
*PV=P values for difference in proportion between dengue and non-dengue
patients using X
2 and Fisher’s exact test.
doi:10.1371/journal.pntd.0001400.t004
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indicator of dengue among adults. Future studies examining the
predictive value of the tourniquet test for the diagnosis of
dengue in adults should evaluate a positive TT in combination
with leucopenia.
As described in previous studies, we found that a positive TT
alone was specific but not sensitive in distinguishing dengue from
other AFI [25,27–29]. This is especially true when the WHO cut-
off of 20 or more petechiae per 2.5 cm
2 is used. As in other studies,
we chose to maximize detection of positive dengue cases (or the
sensitivity of the tourniquet test) by using the cut-off of 10 or more
petechiae per 2.5 cm
2 [13,14,30]. The presence of either a positive
TT or leucopenia correctly identified 94% of patients who had
dengue, and the absence of a positive TT or leucopenia was highly
predictive of the absence of disease with a NPV .98%. That is,
less than 2% of enrolled patients with neither a positive TT nor
leucopenia had dengue.
Compared with the data reported from Thailand on the
combined performance of the TT and leucopenia in identifying
dengue patients, our results showed a lower sensitivity (45%
vs.74%) and PPV (52% vs.73%–83%) but similar specificity (94%
vs. 86%) [14–15]. Our finding of lower sensitivity most likely
reflects differences in study design. These previous studies
primarily enrolled hospitalized patients who then received daily
TTs until the day of defervescence. Our study participants had a
single TT performed at initial presentation to the ED. Previous
research has demonstrated that the sensitivity of the TT depends
on repeated testing and the timing of the test with respect to the
day of illness with sensitivity increasing as a patient nears
defervescence [14,26]. Most (68%) of our participants were
enrolled within three days of symptom onset so that the sensitivity
of the TT found in our study corresponds to the day 24/day 23
values found in the study from Thailand (52% versus 46%–56%)
[14]. We feel that using values solely from the time of initial
patient contact is more useful, as it uses only information that is
available to physicians at the time of initial triage.
Given that the study was performed in the setting of a
concomitant influenza pandemic (CDC, unpublished data) and
we did not restrict enrollment to suspected dengue cases that
required hospitalization, our study also provides data on the
performance of these triage criteria for dengue during periods of
high influenza transmission. The lower PPV in our study largely
reflects the effect of the study being conducted among patients
with AFI (versus only those suspected of having dengue) at the time
of a major outbreak of another AFI. While the specificity and PPV
of the combination of tests was lower when cases with pandemic
influenza A H1N1 were included, overall performance was still
good. Reanalyzing the data after excluding influenza cases resulted
in a PPV for the combination of leucopenia and positive TT of
74%, similar to previously published estimates [14,15]. As only
12% of patients without dengue or influenza had leucopenia in our
study, there was only a minor decrease in the NPV upon excluding
influenza patients for the combination of leucopenia and positive
TT (92% vs 84%).
Our study has some important limitations. It was performed at
an ED in a tertiary-level referral hospital with a large catchment
area, and patients seeking care at this facility are more likely to
have severe disease than patients who seek care at lower-level
facilities. Thus, dengue cases in our study were likely not
representative of the whole spectrum of dengue occurring in
Puerto Rico. Data were missing on TT and white blood cell count
results for approximately 12% and 2% percent of patients,
respectively. The 35 participants who did not have a TT
performed did not differ significantly from those who did have a
TT performed in terms of sex or median age. No cases of dengue
were diagnosed among the patients who did not have a TT
performed. In most cases, only one serum specimen was available
for dengue testing, leading to the possibility that some true dengue
cases were not detected and misclassified as dengue negative. A
comprehensive testing strategy, including a highly sensitive, single-
plex anti-DENV RT-PCR, a NS-1 assay, and a MAC ELISA, was
used to try to limit the amount of this misclassification bias.
The effects of dengue serotype and immunological status
(primary versus secondary dengue infection) on the incidence of
a positive TT or leucopenia have not yet been sufficiently
investigated. Few studies have examined the role of these
variables on the performance of these tests and these studies
have usually been relatively small. Even fewer studies have had
an adequate number of cases with both virological confirmation
and immunological data to look at both variables simultaneously
and stratify serotype specific results by immunological status, an
important potential confounder. A positive TT was more
frequently seen in children with dengue in Nicaragua when
DENV-1 was the predominant serotype compared to an era
when DENV-2 was circulating widely [31]. However this
difference was not evident in the sub-group of virologically
confirmed cases and the study did not stratify between primary
and secondary infections. No difference in white blood cell
count was seen between 385 adults with DENV-2 or DENV-3
infection in Taiwan [32], but significantly more DENV-3
patients had secondary infections making accurate comparisons
between groups difficult. No differences were seen in the
proportion of European travelers with a positive TT between
patients with a primary or secondary immune response [33], but
the small number of patients with a secondary immune response
limited the power of the study. No significant differences for TT
positivity or leukocyte count in primary and secondary
infections were seen among 89 hospitalized DENV-1 patients
in Fiji [34].
Overall our study indicates that a combination of two rapid,
widely available tests can assist clinicians in distinguishing dengue
from other AFIs that have similar clinical signs and symptoms.
Previous investigators have reported that the combination of the
TT and leucopenia is more accurate in identifying patients with
dengue than the World Health Organization’s 1997 clinical case
definition [15], and our data supports the contention that few
patients with dengue are likely to be missed when these criteria
are used. Twenty-nine of the 31 laboratory-positive dengue
patients had either a positive TT or leucopenia. The two dengue
patients that were not detected by these two tests were
thrombocytopenic.
Our study and others [31] suggest that the TT may be useful in
identifying dengue patients before a major decrease in platelet
count, a group for whom dengue is often overlooked as a
diagnostic possibility in Puerto Rico. Patients in our study
population with AFI who had a negative TT and normal WBC
appear to be at low risk of having dengue, and patients with both
leucopenia and a positive TT have a high likelihood of having
dengue, even in the setting of an outbreak of another clinically
similar illness. Increased emphasis should be placed on determin-
ing the usefulness of the TT in combination with white blood cell
count in identifying patients with dengue in Puerto Rico and
elsewhere in the Americas. Further exploration of the sensitivity,
specificity and predictive value of these tests by day of illness would
be of particular benefit for clinical decision making. Additional
larger studies should also be conducted to explore the effect of
dengue serotype and immune status on the diagnostic perfor-
mance of these tests.
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